Reuters -- U.S. health regulators are weighing possible action after results from a clinical trial suggested increased death in liver transplant patients switched to Wyeth’s transplant drug Rapamune.
Reuters -- U.S. health regulators are weighing possible action after results from a clinical trial suggested increased death in liver transplant patients switched to Wyeth’s transplant drug Rapamune.
